Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT1 | P17948 | 5/20 | 0.69 |
| ▸ | KDR | P35968 | 14/20 | 0.49 |
| ▸ | FGFR1 | P11362 | 13/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 11/20 | 0.49 |
| ▸ | ZAP70 | P43403 | 4/20 | 0.49 |
| ▸ | EGFR | P00533 | 5/20 | 0.48 |
| ▸ | ALK | Q9UM73 | 5/20 | 0.47 |
| ▸ | RET | P07949 | 4/20 | 0.47 |
| ▸ | FLT3 | P36888 | 4/20 | 0.47 |
| ▸ | AURKA | O14965 | 4/20 | 0.47 |
| ▸ | MAP4K2 | Q12851 | 3/20 | 0.47 |
| ▸ | STK3 | Q13188 | 3/20 | 0.47 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.47 |
| ▸ | CSF1R | P07333 | 3/20 | 0.47 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.47 |
| ▸ | FLT4 | P35916 | 3/20 | 0.47 |
| ▸ | PLK4 | O00444 | 2/20 | 0.47 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.47 |
| ▸ | JAK2 | O60674 | 2/20 | 0.47 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5829811 | 1.00 | FLT1 (0.69) | FLT1KDRFGFR1PDGFRBZAP70 | |
| SCHEMBL1395372 | 0.89 | FLT1 (0.55) | FLT1KDRFGFR1PDGFRBZAP70 | |
| SCHEMBL1394792 | 0.89 | FLT1 (0.55) | FLT1KDRFGFR1PDGFRBZAP70 | |
| SCHEMBL1395082 | 0.84 | ALK (0.47) | FLT1KDRFGFR1PDGFRBZAP70 | |
| SCHEMBL5829913 | 0.84 | ALK (0.47) | FLT1KDRFGFR1PDGFRBZAP70 | |
| SCHEMBL5830178 | 0.84 | KDR (0.69) | FLT1KDRFGFR1PDGFRBZAP70 | |
| SCHEMBL1395367 | 0.84 | KDR (0.69) | FLT1KDRFGFR1PDGFRBZAP70 | |
| SCHEMBL1395430 | 0.82 | RET (0.63) | FLT1KDRFGFR1PDGFRBZAP70 | |
| SCHEMBL1395428 | 0.82 | RET (0.63) | FLT1KDRFGFR1PDGFRBZAP70 | |
| SCHEMBL4457322 | 0.82 | FLT1 (1.00) | FLT1KDRFGFR1PDGFRBZAP70 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7053086-B2 | 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors | SUGEN, INC. (US) | 2006-05-30 | — | — | US | disclosed |
| US-20040097497-A1 | 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors | SUGEN, INC. | 2004-05-20 | — | — | US | disclosed |
| US-6635640-B2 | 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors | SUGEN, INC. | 2003-10-21 | — | — | US | disclosed |
| EP-1296975-A1 | 4-HETEROARYL-3-HETEROARYLIDENYL-2-INDOLINONES AND THEIR USE AS PROTEIN KINASE INHIBITORS | Sugen, Inc. (US) | 2003-04-02 | — | — | EP | disclosed |
| US-20020187978-A1 | 4-Heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors | SUGEN, INC. | 2002-12-12 | — | — | US | disclosed |
| WO-2002002551-A1 | 4-HETEROARYL-3-HETEROARYLIDENYL-2-INDOLINONES AND THEIR USE AS PROTEIN KINASE INHIBITORS | SUGEN, INC. (US) | 2002-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020187978-A1 | 4-Heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors | CDK2, CDK20, CDK3 | FLT1 2991/4885KDR 1114/4885FGFR1 785/4885 |
| US-20040097497-A1 | 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors | CDK2, CDK20, CDK3 | FLT1 2991/4885KDR 1114/4885FGFR1 785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.